21 completed, 5 terminated, 2 active not recruiting, 2 recruiting. 16 Phase 2, 5 Phase 3, 4 Phase 1, 2 Not applicable.
Follow Dendreon: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer Sipuleucel-T, N803 - Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 30 | 2026-11-30 | 2026-08-10 |
| Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC Testosterone Cypionate, Sipuleucel-T - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Yale University | 26 | 2023-12-20 | 2026-09-10 |
| Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer Sipuleucel-T - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 | Active not recruiting | University of Oklahoma | 15 | 2023-11-12 | 2026-05-27 |
| Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T Sipuleucel-T Injection - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Recruiting | Dendreon | 400 | 2023-10-02 | 2025-08-27 |
| Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer Abiraterone, Enzalutamide, Apalutamide - Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 26 | 2023-02-14 | 2026-09-15 |
| Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer sipuleucel-T - Adenocarcinoma of the Prostate | Phase 3 | Completed | Dendreon | 532 | 2018-10-18 | 2024-10-08 |
| Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer Atezolizumab1200 mg IV, Sipuleucel-T - Prostate Cancer Metastatic | Phase 1 | Completed | University of Hawaii | 37 | 2017-02-06 | 2021-05-26 |
| Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC Radium-223, Sipuleucel-T - Prostate Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 36 | 2016-02-22 | 2021-07-08 |
| A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T Provenge - Castrate Refractory Metastatic Prostate Cancer (mCRPC) | Completed | GenesisCare USA | 20 | 2014-06-01 | 2019-01-09 | |
| Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer SipT Treatment, Ipilimumab - Prostate Cancer | Phase 2 | Completed | University of California, San Francisco | 50 | 2014-04-22 | 2021-08-18 |
| PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer PET/CT, PET/MRI - Prostate Cancer | Not applicable | Terminated | NYU Langone Health | 10 | 2014-01-01 | 2017-07-18 |
| A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer sipuleucel-T, enzalutamide - Metastatic Prostate Cancer | Phase 2 | Completed | Dendreon | 52 | 2013-09-01 | 2018-10-24 |
| Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T Laboratory Biomarker Analysis, Radiation Therapy - Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone | Not applicable | Completed | Roswell Park Cancer Institute | 15 | 2013-07-03 | 2021-08-05 |
| Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer sipuleucel-T, DNA Vaccine - Prostate Cancer | Phase 2 | Completed | University of Wisconsin, Madison | 18 | 2013-05-20 | 2021-06-18 |
| Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T Sipuleucel-T - Prostate Cancer | Terminated | Dendreon | 139 | 2012-10-01 | 2019-08-19 | |
| Sipuleucel-T Manufacturing Demonstration Study sipuleucel-T - Cancer of Prostate, Cancer of the Prostate | Phase 2 | Completed | Dendreon | 47 | 2012-06-01 | 2015-12-09 |
| Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer Castration-Resistant Prostate Cancer | Terminated | Dendreon | 225 | 2012-01-01 | 2019-08-28 | |
| Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer sipuleucel-T, abiraterone acetate - Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer | Phase 2 | Completed | Dendreon | 69 | 2011-12-01 | 2019-03-19 |
| Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer sipuleucel-T - Prostate Cancer | Phase 2 | Terminated | Dendreon | 8 | 2011-12-01 | 2017-06-05 |
| Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer sipuleucel-T, leuprolide acetate - Prostatic Neoplasm, Prostate Cancer | Phase 2 | Completed | Dendreon | 68 | 2011-09-01 | 2017-05-30 |
Showing 20 of 31. Sign in to see all of them.
Prostatic Neoplasms (20) · Neoplasms (4) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Transitional Cell (1) · Disease (1) · Genital Neoplasms, Male (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Prostatic Diseases (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1) · Urinary Bladder Neoplasms (1) · Urogenital Neoplasms (1)
sipuleucel-T (25) · enzalutamide (2) · ALT-803 (1) · Abiraterone Acetate (1) · Immunization, Secondary (1) · Ipilimumab (1) · Leuprolide (1) · Positron Emission Tomography Computed Tomography (1) · Radiation (1) · Radiotherapy (1) · Radium-223 (1) · Standard of Care (1) · Vaccines, DNA (1) · abiraterone (1) · apalutamide (1)
United States (29) · Canada (2) · Austria (1) · France (1) · Netherlands (1) · United Kingdom (1)
Robert Israel, MD (7) · Bruce Brown, MD (4) · Nadeem Sheikh, PhD (2) · Paul Schellhammer, MD (2) · Andrew Stubbs, PhD (1) · Andy Sandler, MD (1) · Anna Ferrari, MD (1) · Benjamin Lowentritt, MD (1) · Douglas McNeel, M.D., PhD (1) · Emmanuel Antonarakis, MD (1) · Eric J. Small, MD (1) · Gurkamal Chatta, MD (1) · Jared Acoba, MD (1) · Jingsong Zhang, MD, PhD (1) · Joseph W Kim, MD (1)
PMID 24957547, PMID 35812443, PMID 37058234, PMID 16809734, PMID 20818862, PMID 23253957, PMID 23896100, PMID 27216195, PMID 29534736, PMID 32111923, PMID 33451978, PMID 33986125, PMID 34376554, PMID 35027313, PMID 35145218